CD274 and non-small cell lung carcinoma: More recently, the NADIM trial, which examined the combination of nivolumab with chemotherapy, has reported superior pathologic complete response (pCR) and MPR rates of 82.9% and 63.4%, respectively, and 36-month progression-free survival (PFS) and overall survival (OS) of 81.1% and 91.0%, respectively, among patients with stage IIIA NSCLC, showing great promise of PD-(L)1 blockade plus chemotherapy in shifting the paradigm of NSCLC (9, 10).